NCT05275777View on ClinicalTrials.gov

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

February 28, 2030

Conditions
HER2-negative Breast CancerAdvanced Solid Tumor
Interventions
DRUG

ADG106

Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.

DRUG

Doxorubicin

Administered as an intravenous infusion.

DRUG

Cyclophosphamide

Administered as an intravenous infusion.

DRUG

Paclitaxel

Administered as an intravenous infusion.

Trial Locations (1)

Unknown

National University Hospital, Singapore

Sponsors

Collaborators (1)

Adagene Inc
All Listed Sponsors
collaborator

Adagene Inc

INDUSTRY

lead

National University Hospital, Singapore

OTHER